Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ERGONASDAQ:INDVNYSE:OGNNASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERGOEntia Biosciences$0.00-50.0%$0.00$0.00▼$0.00N/A12.3150 shs78,461 shsINDVIndivior$11.98+3.7%$9.75$7.33▼$18.59$1.65B0.93985,869 shs914,871 shsOGNOrganon & Co.$9.60+1.6%$13.46$9.18▼$23.10$2.50B0.732.90 million shs13.58 million shsSLSSELLAS Life Sciences Group$1.74+7.4%$1.21$0.77▼$1.84$164.51M2.531.37 million shs4.35 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERGOEntia Biosciences0.00%0.00%0.00%0.00%0.00%INDVIndivior+3.72%+3.63%+25.84%+0.67%-32.05%OGNOrganon & Co.+1.69%-21.38%-34.87%-38.40%-49.04%SLSSELLAS Life Sciences Group+7.41%+24.29%+59.63%+7.41%+35.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AINDVIndivior3.38 of 5 stars3.63.00.00.02.71.71.9OGNOrganon & Co.4.7313 of 5 stars3.01.03.33.73.11.73.1SLSSELLAS Life Sciences Group0.8391 of 5 stars0.04.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERGOEntia Biosciences 0.00N/AN/AN/AINDVIndivior 3.25Buy$15.0025.21% UpsideOGNOrganon & Co. 2.00Hold$19.67104.86% UpsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OGN, INDV, SLS, and ERGO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025OGNOrganon & Co.Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline4/9/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.003/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.002/14/2025OGNOrganon & Co.BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $24.002/14/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AINDVIndivior$1.17B1.41$2.43 per share4.94N/A∞OGNOrganon & Co.$6.40B0.39$3.08 per share3.12($0.27) per share-35.56SLSSELLAS Life Sciences Group$1M164.51N/AN/A($0.25) per share-6.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERGOEntia BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/AINDVIndivior$2M-$0.31N/A7.01N/A-3.96%-241.73%15.09%N/AOGNOrganon & Co.$864M$3.332.882.570.9013.49%431.62%8.03%N/ASLSSELLAS Life Sciences Group-$37.34M-$0.52N/AN/AN/AN/A-629.46%-178.65%5/13/2025 (Estimated)Latest OGN, INDV, SLS, and ERGO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067N/AN/AN/AN/AN/A5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/A2/20/2025Q4 2024INDVIndivior$0.32$0.32N/A$0.07$262.35 million$298.00 million2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERGOEntia BiosciencesN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AOGNOrganon & Co.$1.1211.67%+25.99%33.63%N/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ALatest OGN, INDV, SLS, and ERGO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/20252/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERGOEntia BiosciencesN/AN/AN/AINDVIndiviorN/A0.830.65OGNOrganon & Co.17.731.701.21SLSSELLAS Life Sciences GroupN/A2.262.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERGOEntia BiosciencesN/AINDVIndivior60.33%OGNOrganon & Co.77.43%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipERGOEntia Biosciences28.30%INDVIndiviorN/AOGNOrganon & Co.1.40%SLSSELLAS Life Sciences Group1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERGOEntia Biosciences6N/AN/ANot OptionableINDVIndivior1,164137.88 millionN/ANot OptionableOGNOrganon & Co.10,000259.96 million253.93 millionNot OptionableSLSSELLAS Life Sciences Group1094.55 million69.54 millionNot OptionableOGN, INDV, SLS, and ERGO HeadlinesRecent News About These CompaniesSELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025April 28, 2025 | quiverquant.comSELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR ConferenceApril 28, 2025 | globenewswire.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%April 26, 2025 | aaii.comSELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher - Time to Buy?April 26, 2025 | marketbeat.comSELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual MeetingApril 23, 2025 | quiverquant.comSELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comSellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trialApril 9, 2025 | markets.businessinsider.comSELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AMLApril 8, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common Stock (SLS) Insider ActivityMarch 30, 2025 | nasdaq.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deSELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 20, 2025 | globenewswire.comSellas reports Phase IIa trial data of SLS009 for DLBCL treatmentFebruary 21, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | finanznachrichten.deSELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trialFebruary 20, 2025 | msn.comSellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCLFebruary 20, 2025 | markets.businessinsider.comSELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL PatientsFebruary 20, 2025 | quiverquant.comSELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | globenewswire.comSellas Life Sciences Group Inc (SLS) Stock: Understanding Its Underlying ValueFebruary 3, 2025 | bovnews.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 21.80%February 1, 2025 | aaii.comSellas Life Sciences Group Inc (SLS) Stock Dilemma: A Surge That Has Everyone Talking—What’s the Real Story?January 30, 2025 | bovnews.comSellas $25M registered direct offering priced at $1.27 per share and warrantJanuary 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOGN, INDV, SLS, and ERGO Company DescriptionsEntia Biosciences OTCMKTS:ERGO$0.0001 0.00 (-50.00%) As of 05/2/2025 02:13 PM EasternEntia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.Indivior NASDAQ:INDV$11.98 +0.43 (+3.72%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$11.80 -0.18 (-1.49%) As of 05/2/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Organon & Co. NYSE:OGN$9.60 +0.15 (+1.59%) Closing price 05/2/2025 03:59 PM EasternExtended Trading$9.56 -0.04 (-0.36%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.SELLAS Life Sciences Group NASDAQ:SLS$1.74 +0.12 (+7.41%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.73 -0.01 (-0.57%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
